BioNTech (NASDAQ:BNTX) Earns “Buy” Rating from Deutsche Bank Aktiengesellschaft

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday,MarketScreener reports.

BNTX has been the subject of a number of other research reports. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. UBS Group raised shares of BioNTech to a “hold” rating in a report on Thursday, December 4th. Jefferies Financial Group decreased their target price on BioNTech from $151.00 to $138.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Citigroup dropped their price target on BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Thirteen equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.73.

BioNTech Stock Up 1.3%

Shares of BNTX opened at $91.73 on Tuesday. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company’s fifty day moving average is $106.30 and its two-hundred day moving average is $102.46. The firm has a market cap of $22.01 billion, a PE ratio of -17.48 and a beta of 1.51. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

Institutional Trading of BioNTech

Hedge funds have recently modified their holdings of the business. Dodge & Cox boosted its holdings in shares of BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after buying an additional 2,769,654 shares during the period. GSK plc acquired a new stake in shares of BioNTech in the fourth quarter valued at about $84,711,000. BNP Paribas Financial Markets grew its position in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Bank of America Corp DE increased its stake in shares of BioNTech by 344.4% in the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after purchasing an additional 444,332 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in shares of BioNTech during the 4th quarter worth about $41,656,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.